Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05422248




Registration number
NCT05422248
Ethics application status
Date submitted
13/06/2022
Date registered
16/06/2022
Date last updated
13/09/2023

Titles & IDs
Public title
Oxygen Wound Therapy Feasibility Study
Scientific title
Oxygen Wound Therapy Feasibility Study
Secondary ID [1] 0 0
CIA-297
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Leg Ulcer 0 0
Condition category
Condition code
Skin 0 0 0 0
Other skin conditions
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Series Topical Oxygen Therapy
Treatment: Devices - Paired Topical Oxygen Therapy

Active Comparator: Series - Standard wound care for 4 weeks followed by intervention device wound care for up to 12 weeks.

Active Comparator: Paired - Intervention device wound care to a portion of wound and standard wound care to the remaining portion of the wound, for up to 12 weeks.


Treatment: Devices: Series Topical Oxygen Therapy
Standard care provided to the whole wound followed by intervention device care to the whole wound.

Treatment: Devices: Paired Topical Oxygen Therapy
Care provided to one portion of wound by intervention device and standard care to remaining portion of wound.

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in wound area
Timepoint [1] 0 0
12 weeks

Eligibility
Key inclusion criteria
- Patients with hard to heal lower leg wounds as determined by the treating clinician.

- Patient has a wound area greater than the area of the interface

- Aged 16 years and over

- Able to provide informed consent
Minimum age
16 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Lower limb wounds with bone or tendon exposed

- Infected wounds which require treatment with antibiotics

- Wounds with critical bioburden requiring a medicated dressing

- Wounds that require dressing changes more than every second day, for example high
exudating wounds

- Wounds with slough covering more than 30% of the wound surface

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Otago

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Fisher and Paykel Healthcare
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Determine the feasibility of using a new topical oxygen therapy device to treat hard to heal
lower leg wounds.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05422248
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jolanta Krysa
Address 0 0
Southern DHB Vascular Surgery
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Geoff Bold
Address 0 0
Country 0 0
Phone 0 0
+64 (09) 574 0100
Fax 0 0
Email 0 0
geoff.bold@fphcare.co.nz
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05422248